Investors

Cortical’s principal investor is GBS Venture Partners. Other investors include Genzyme Cororation, Start-Up Australia Ventures, and Monash University.  

GBS Venture Partners (GBS) is a leading life science venture capital group resulting from a November 2002 management buyout of Rothschild Bioscience Managers Limited from NM Rothschild & Sons (Aust) Ltd. GBS invests in and adds value to unlisted high growth companies involved in innovative technologies such as:

    * human therapeutics and diagnostics

    * animal therapeutics and diagnostics

    * medical devices

    * health information technology

    * agribusiness, food and environmental technology

GBS invests at the seed, start-up or early expansion stage of company development. 

Genzyme Corporation is a global biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. The company's broad product portfolio is focused on rare genetic disorders, renal disease, osteoarthritis and immune-mediated diseases, and includes an industry-leading array of diagnostic products and services. Genzyme's commitment to innovation continues today with research into novel approaches to cancer, heart disease, and other areas of unmet medical need. More than 5,000 Genzyme employees in offices around the globe serve patients in over 80 countries .